AcelRx Pharmaceuticals, Inc. to Post FY2023 Earnings of Per Share, HC Wainwright Forecasts
ACRXDelisted Stock | USD 1.01 0.01 1.00% |
Slightly above 50% of AcelRx Pharmaceuticals' investors are presently thinking to get in. The analysis of current outlook of investing in AcelRx Pharmaceuticals suggests that some traders are interested regarding AcelRx Pharmaceuticals' prospects. AcelRx Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, AcelRx Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
AcelRx |
AcelRx Pharmaceuticals, Inc. Analysts at HC Wainwright boosted their FY2023 EPS estimates for shares of AcelRx Pharmaceuticals in a research note issued to investors on Thursday, November 9th. HC Wainwright analyst E. Arce now expects that the specialty pharmaceutical company will post earnings of per share for the year,
Read at thelincolnianonline.com
AcelRx Pharmaceuticals Fundamental Analysis
We analyze AcelRx Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AcelRx Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AcelRx Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Liabilities
Current Liabilities Comparative Analysis
AcelRx Pharmaceuticals is currently under evaluation in current liabilities category among its peers. Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
AcelRx Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with AcelRx Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of AcelRx Pharmaceuticals could also be used in its relative valuation, which is a method of valuing AcelRx Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
AcelRx Pharmaceuticals Related Equities
ASRT | Assertio Therapeutics | 4.06 | ||||
LFCR | Lifecore Biomedical | 2.93 | ||||
AMRX | Amneal Pharmaceuticals, | 1.29 | ||||
TLRY | Tilray | 0.88 | ||||
ORGO | Organogenesis Holdings | 0.85 | ||||
AQST | Aquestive Therapeutics | 1.60 | ||||
EVOK | Evoke Pharma | 2.65 | ||||
SHPH | Shuttle Pharmaceuticals | 3.60 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Other Consideration for investing in AcelRx Stock
If you are still planning to invest in AcelRx Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the AcelRx Pharmaceuticals' history and understand the potential risks before investing.
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
CEOs Directory Screen CEOs from public companies around the world | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation |